Sort
40,608 grants matching “prostate cancer”
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
$927,566Sudhir Sahasrabudhe · Jsk Therapeutics, Inc. · R44 · FY2012 · CA
Small-molecule therapy for metastatic castration-resistant prostate cancer
$927,358Daqing Wu · Metcure Therapeutics, Llc · R42 · FY2022 · CA
Collaborative Protein Technology Resource - Nano-Scale Protein Analysis Section
$926,839Jinqiu Chen · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA
THERAPEUTIC TARGETING OF NOX2 TO TARGET BONE METASTATIC PROSTATE CANCER PROGRESSION AND IMMUNE EVASION
$926,248The Geneva Foundation · · FY2021 · Defense Health Agency
KanSurvive 2.0
$926,040K Allen Greiner · University Of Kansas Medical Center · U01 · FY2025 · CA
Stromal Regulation of Bone Metastasis
$925,878Raghu Kalluri · Beth Israel Deaconess Medical Center · U54 · FY2011 · CA
CDK12 IS A CONTEXT-SPECIFIC TUMORIGENESIS REGULATOR AND NOVEL THERAPEUTIC TARGET IN CASTRATION-RESISTANT PROSTATE CANCER.
$925,834Regents Of The University Of Michigan · · FY2021 · Department of the Army
Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level
$925,687Andrea Califano · Columbia University Health Sciences · U01 · FY2024 · CA
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development
$925,560Gunnar Joerg Floris Kaufmann · Oncternal Therapeutics, Inc. · R44 · FY2021 · CA
Paul Calabresi Program in Clinical-Translational Research at Mayo Clinic
$924,979Aminah Jatoi · Mayo Clinic Rochester · K12 · FY2012 · CA
PEER-BASED INTERVENTION FOR GENETIC EVALUATION FOR PROSTATE CANCER AMONG AFRICAN AMERICAN MEN: THE PEER GENETIC STUDY AWARD
$924,401Thomas Jefferson University · · FY2019 · Defense Health Agency
Shared Resource: Comparative Medicine
$924,350Rajesh Uthamanthil · Fred Hutchinson Cancer Research Center · P30 · FY2017 · CA
A NOVEL REGULATOR FOR THE EXIT OF BONE-RESIDENT PROSTATE CANCER CELLS FROM DORMANCY
$924,000Wayne State University · · FY2019 · Defense Health Agency
Signal Transduction Events and the Regulation of Cell Growth
$923,994Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2019 · CA
Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic
$923,913Beatrice Langton-Webster · Cancer Targeted Technology, Llc · R44 · FY2016 · CA
Clinical Production and IND enabling Studies for PSCA Minibody Imaging in Pancrea
$923,853Bradley T Wyman · Imaginab, Inc. · R44 · FY2012 · CA
Community Outreach and Engagement
$923,372Jason A Mendoza · Fred Hutchinson Cancer Center · P30 · FY2025 · CA
Data Processing, Analysis and Modeling Unit
$923,254Jeremy Goecks · Oregon Health & Science University · U2C · FY2023 · CA
Comprehensive proteomic profiling of the ubiquitin pathway in cancer
$923,128Dieter A Wolf · Sanford Burnham Prebys Medical Discovery Institute · RC2 · FY2009 · CA
Novel Targets for Vaccine Therapy
$923,127Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Participant Engagement Unit
$922,915Andrew Louis Sussman · University Of New Mexico Health Scis Ctr · U2C · FY2025 · CA
MOLECULAR CLASSIFICATION OF PROSTATE CANCER
$922,826Sloan-Kettering Institute For Cancer Res · U01 · FY2000 · CA
A NOVEL REGULATOR OF CANCER STEM CELL PLASTICITY AND ITS ROLES IN PROSTATE CANCER RESISTANCE AND METASTASIS
$922,183Emory University · · FY2018 · Defense Health Agency
Characterization of Cancer Stem Cells
$922,149William Farrar · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
ELUCIDATING THE METABOLOMIC PROFILE OF FATAL PROSTATE CANCER
$922,056Regents Of The University Of Michigan · · FY2018 · Defense Health Agency